dc.creator | González-Serna Martín, Manuel Alejandro | es |
dc.creator | Macías Sánchez, Juan | es |
dc.creator | Corma Gómez, Anaïs | es |
dc.creator | Tellez, Francisco | es |
dc.creator | Cucurull, Josep | es |
dc.creator | Real Navarrete, Luis Miguel | es |
dc.creator | Granados, Rafael | es |
dc.creator | Rivero Juárez, Antonio | es |
dc.creator | Hernández Quero, José | es |
dc.creator | Merino, Dolores | es |
dc.creator | Palacios, Rosario | es |
dc.creator | Ríos-Villegas, María José | es |
dc.creator | Collado, Antonio | es |
dc.creator | Pineda Vergara, Juan Antonio | es |
dc.date.accessioned | 2024-04-05T10:31:59Z | |
dc.date.available | 2024-04-05T10:31:59Z | |
dc.date.issued | 2022-09 | |
dc.identifier.citation | González-Serna Martín, M.A., Macías Sánchez, J., Corma Gómez, A., Tellez, F., Cucurull, J., Real Navarrete, L.M.,...,Pineda Vergara, J.A. (2022). High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use. Journal of Infection, 85 (3), 322-326. https://doi.org/10.1016/j.jinf.2022.06.005. | |
dc.identifier.issn | 0163-4453 | es |
dc.identifier.issn | 1532-2742 | es |
dc.identifier.uri | https://hdl.handle.net/11441/156690 | |
dc.description.abstract | Objectives
Real world data on glecaprevir/pibrentasvir (G/P) among active drug users are scarce. We evaluated the sustained virological response (SVR) rates of G/P among individuals with and without active drug use in routine clinical practice.
Methods
Two ongoing prospective multicenter cohorts of individuals starting G/P were analyzed. Overall SVR intention-to-treat (ITT), discontinuations due to adverse effects and dropouts were evaluated. Results in patients with active, past and without active drug use were compared.
Results
Overall, 644 individuals started G/P and have reached the date of SVR evaluation. Of them, 613 (95.2%) individuals achieved SVR. There were two (0.3%) relapses, one (0.2%) discontinuation due to side effects and 35 (5.4%) dropouts. SVR rates for patients with active drug use, past drug use and those who never used drugs were 85.4%(n/N = 70/82), 96.1%(n/N = 320/333) and 97.4%(n/N = 223/229) respectively (p < 0.001). After adjustment by sex, age, HCV genotype and opioid agonist therapy, active drug use was the only factor independently associated with SVR (ITT) [adjusted OR (95%confidence interval): 0.29(0.09–0.99),p = 0.048].
Conclusions
Active drug use was independently associated with lower SVR rates to G/P, mainly due to voluntary dropout. G/P could be particularly beneficial in this scenario but specific strategies designed to increase the retention in care are needed. | es |
dc.description.sponsorship | Instituto de Salud Carlos III PI018/00606 (Co-funded by European Regional Development Fund/European Social Fund) | es |
dc.description.sponsorship | Ministry of Science, Innovation and Universities of Spain CP18/00146 and CP18/00111 | es |
dc.description.sponsorship | Instituto de Salud Carlos III (CM19/00251) | es |
dc.description.sponsorship | Servicio Andaluz de Salud B-0061-2021 and A1-0060-2021 | es |
dc.format | application/pdf | es |
dc.format.extent | 5 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.relation.ispartof | Journal of Infection, 85 (3), 322-326. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Glecaprevir/pibrentasvir | es |
dc.subject | HCV therapy | es |
dc.subject | Drug use | es |
dc.subject | Opiate agonist therapy | es |
dc.subject | PWID | es |
dc.title | High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/acceptedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Fisiología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.projectID | PI018/00606 | es |
dc.relation.projectID | CP18/00146 | es |
dc.relation.projectID | CP18/00111 | es |
dc.relation.projectID | CM19/00251 | es |
dc.relation.projectID | B-0061-2021 | es |
dc.relation.projectID | A1-0060-2021 | es |
dc.relation.publisherversion | https://dx.doi.org/10.1016/j.jinf.2022.06.005 | es |
dc.identifier.doi | 10.1016/j.jinf.2022.06.005 | es |
dc.journaltitle | Journal of Infection | es |
dc.publication.volumen | 85 | es |
dc.publication.issue | 3 | es |
dc.publication.initialPage | 322 | es |
dc.publication.endPage | 326 | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) | es |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (MICINN). España | es |
dc.contributor.funder | Servicio Andaluz de Salud | es |
dc.description.awardwinning | Premio Trimestral Publicación Científica Destacada de la US. Facultad de Farmacia | |